1. Home
  2. NTRA vs CACI Comparison

NTRA vs CACI Comparison

Compare NTRA & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • CACI
  • Stock Information
  • Founded
  • NTRA 2003
  • CACI 1962
  • Country
  • NTRA United States
  • CACI United States
  • Employees
  • NTRA N/A
  • CACI N/A
  • Industry
  • NTRA Medical Specialities
  • CACI EDP Services
  • Sector
  • NTRA Health Care
  • CACI Technology
  • Exchange
  • NTRA Nasdaq
  • CACI Nasdaq
  • Market Cap
  • NTRA 20.6B
  • CACI 9.2B
  • IPO Year
  • NTRA 2015
  • CACI 1979
  • Fundamental
  • Price
  • NTRA $159.62
  • CACI $412.23
  • Analyst Decision
  • NTRA Strong Buy
  • CACI Buy
  • Analyst Count
  • NTRA 15
  • CACI 11
  • Target Price
  • NTRA $152.67
  • CACI $521.20
  • AVG Volume (30 Days)
  • NTRA 1.1M
  • CACI 224.8K
  • Earning Date
  • NTRA 02-26-2025
  • CACI 01-22-2025
  • Dividend Yield
  • NTRA N/A
  • CACI N/A
  • EPS Growth
  • NTRA N/A
  • CACI 22.78
  • EPS
  • NTRA N/A
  • CACI 20.19
  • Revenue
  • NTRA $1,531,955,000.00
  • CACI $7,866,574,000.00
  • Revenue This Year
  • NTRA $53.71
  • CACI $13.55
  • Revenue Next Year
  • NTRA $11.00
  • CACI $7.35
  • P/E Ratio
  • NTRA N/A
  • CACI $20.01
  • Revenue Growth
  • NTRA 54.94
  • CACI 13.24
  • 52 Week Low
  • NTRA $58.53
  • CACI $314.06
  • 52 Week High
  • NTRA $175.63
  • CACI $588.26
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 51.07
  • CACI 39.07
  • Support Level
  • NTRA $155.12
  • CACI $400.01
  • Resistance Level
  • NTRA $161.53
  • CACI $409.33
  • Average True Range (ATR)
  • NTRA 5.56
  • CACI 10.80
  • MACD
  • NTRA -1.63
  • CACI 3.01
  • Stochastic Oscillator
  • NTRA 37.59
  • CACI 76.11

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

Share on Social Networks: